Background {#Sec1}
==========

Osteonecrosis of femoral head (ONFH) is a kind of orthopedic refractory disease that cellular death happens within femoral head owing to damage of blood supply to the anterior-superior-lateral part of the femoral head \[[@CR1]\]. In China, there are approximately 7 million people with ONFH currently. And, new cases reached to 100--200 thousand each year \[[@CR2]\]. ONFH is a complex disorder may result from various risk factors such as trauma, alcoholism, coagulation defects, and abnormal lipid metabolism. Recent study suggested that abnormal lipid metabolism is main pathogenesis of osteonecrosis \[[@CR3]\]. Hyperlipidemia affects the microcirculation of the femoral head to result in femoral necrosis from multiple links, such as affecting blood coagulation solvent systems, influencing bone fat embolism, and affecting the formation of bone micro-thrombosis \[[@CR4],[@CR5]\]. ApoA5 is an important apolipoprotein which involved in plasma lipid metabolism. The most significant impact on plasma triglycerides (TG) levels seems to be associated with *ApoA5* gene (ID 116519, OMIM accession number 606368) variants \[[@CR6],[@CR7]\]. *ApoA5* is located on TG-rich and high density lipoprotein (HDL) particles, enhances the activity of lipoprotein lipase \[[@CR7],[@CR8]\], and recombinant apoA5 binds to the LDL receptor family members \[[@CR9]\]. Previous studies suggested that minor alleles of two SNPs (rs662799 and rs3135506) in *ApoA5* gene were associated with elevated plasma TG levels, regardless of ethnicity and sex \[[@CR10]--[@CR13]\].

In 2007, Hirata et al. \[[@CR14]\] found *ApoB* gene polymorphism was associated with osteonecrosis. Subsequently, Wang et al. \[[@CR15]\] found -75G \> A polymorphism in *ApoAI* gene was associated with osteonecrosis in Chinese population. Recently, Yin et al. also found SNPs in *ApoAI* gene were associated with ONFH in a Chinese Han population \[[@CR16]\]. However, the relation between the polymorphisms of *ApoA5* gene and ONFH has not been studied.

In the present study, we designed a case--control study to reveal the relation between *ApoA5* genetic polymorphisms and ONFH in a Chinese population.

Subjects and methods {#Sec2}
--------------------

### Ethics {#Sec3}

The present study has been performed with the approval of the ethics committee of the 5th Affiliated Hospital of Xinjiang Medical University and was in compliance with the Helsinki Declaration. The informed consents of the study were collected from all the candidate subjects.

### Subjects {#Sec4}

All the patients were selected from January 2001 to December 2013 in the 5th Affiliated Hospital of Xinjiang Medical University. All the patients were consistent with the diagnostic criteria of osteonecrosis proposed in 1995 by Mont et al. \[[@CR17]\]. Steroid-induced ONFH was defined by a history of a mean daily dose of ≥ 16.6 mg or highest daily dose of 80 mg of predinosolone equivalent within 1 year prior to the development of symptoms or radiological diagnosis in asymptomatic cases \[[@CR18]--[@CR20]\]. All the patients were confirmed by clinical diagnosis, double hip X-ray image, CT scan or MRI examination. We included 223 patients with steroid-induced ONFH (case group, 121 men, 102 women; mean age: 42.27 ± 15.71 years) and 201 patients who did not develop steroid-induced ONFH (control group, 112 men, 89 women; mean age: 43.33 ± 15.02 years) following steroid administration for the present study. The clinical characteristics of patients in case and control groups were summarized in Table [1](#Tab1){ref-type="table"}.Table 1**Characteristics of the participantsGroupsNAge (years)Gender (M/F)BMI Kg/m** ^**2**^**GLU (mmol/L)TG (mmol/L)TC (mmol/L)HDL-C (mmol/L)LDL-C (mmol/L)**ONFH group22342.27 ± 15.71121/10223.7 ± 3.55.8 ± 1.42.5 ± 1.15.3 ± 2.41.5 ± 0.72.9 ± 1.6Control group20143.33 ± 15.02112/8923.9 ± 3.25.7 ± 1.21.4 ± 1.34.6 ± 2.11.4 ± 0.82.2 ± 1.4*P*0.7030.6540.2610.352\<0.0010.0010.1840.007Note: BMI = Body mass index; GLU = Glucose; TC = Total cholesterol; LDL-C = Low-density lipoprotein-cholesterol; LDL-C = High-density lipoprotein-cholesterol; TG = Triglycerides.

### SNPs selection and genotyping {#Sec5}

Two SNPs (rs662799 and rs3135506), which were reported to be associated with plasma lipid level, in the *ApoA5* gene were selected in this study. Blood samples were collected using a standard venipuncture technique and EDTA-containing tubes. DNA was extracted from peripheral vein blood leukocytes using a whole blood genome extraction kit (Beijing Boiteke Corporation, Beijing, China). SNPs rs662799 and rs3135506 were genotyped using PCR-RFLP as described in details elsewhere \[[@CR21]--[@CR23]\]. Briefly, polymerase chain reaction (PCR) was performed in a volume of 25 ml containing 200 ng of genomic DNA. The amounts of Mg^2+^, dNTP, and DNA polymerase (Bangalore Genei, India) used in each reaction were 1.5 mM, 200 mM, and 1 U, respectively. The thermal cycles started with 94°C for 4 min and were followed by 35 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 30 s. A total volume of 20 ul containing 20 U endonuclease was added directly to the PCR product and digested at 37°C overnight. After electrophoresis, the digested products were visualized on a 3% polyacrylamide gel with ethidium bromide staining.

Statistical analysis {#Sec6}
--------------------

Data were analyzed using SPSS 17.0 software package (Chicago, IL, USA).The genotype and allele frequencies were calculated by direct counting method. The differences of genotype and allele distributions between case and control groups were compared using χ2 test, OR value and its 95% CI was calculated according to χ2 test. Normality was assessed by plotting the residuals. Statistical significance was set at p \<0.05.

Results {#Sec7}
=======

Characteristics of participants {#Sec8}
-------------------------------

The characteristics of 223 patients and 201 control subjects were shown in Table [1](#Tab1){ref-type="table"}. After the statistical analysis, there were no significant differences in the distribution of age, sex, body mass index (BMI), GLU, and HDL-C between the two groups. However, there were significant differences in TG, TC and LDL-C between these two groups.

Hardy-Weinberg equilibrium {#Sec9}
--------------------------

The genotype distributions were in Hardy-Weinberg equilibrium in both case group and control group (both P \> 0.05, data not shown).

Genotype and allele frequency distributions {#Sec10}
-------------------------------------------

These two SNPs had a strong association with ONFH in all genetic models (As shown in Table [2](#Tab2){ref-type="table"}).To determine the extent of linkage disequilibrium (LD) between the two polymorphisms, standardized LD coefficient D' and r^2^ were calculated (D' = 0.65, and r^2^ = 0.12).Table 2**Genotypic distribution of ApoA5 polymorphismsSNPModelControlsPatientsOR (95% CI)P value**rs662799CodominantTT192 (95.51)146 (65.2)1TC3 (1.49)30 (13.2)10.33 (2.54-52.77)\<0.001CC6 (3.0)47 (21.6)15.32 (4.12-55.67)\<0.001DominantTT192 (95.51)146 (65.2)1TC + CC9 (4.49)77 (34.8)12.11 (4.33-36.21)\<0.001RecessiveTT + TC195 (97.0)176 (78.4)1CC6 (3.0)47 (21.6)13.33 (3.21-44.05)\<0.001rs3135506CodominantCC176 (87.51)159 (70.98)1CG22 (11.0)32 (14.29)1.43 (0.82-3.76)0.088GG3 (1.49)33 (14.73)12.11 (3.66-67.12)\<0.001DominantCC176 (87.51)159 (70.98)1CG + GG25 (12.49)65 (29.02)3.01 (1.98-6.33)\<0.001RecessiveCC + CG196 (98.51)191 (85.27)1CC3 (1.49)33 (14.73)12.22 (2.12-50.76)\<0.001

Haplotype analysis of rs662799 and rs3135506 {#Sec11}
--------------------------------------------

To examine the combined effect of the two SNPs (rs662799 and rs3135506) in the *ApoA5* gene, we constructed 4 haplotypes between the two SNPs. As shown in Table [3](#Tab3){ref-type="table"}, T-C haplotype was associated with decreased risk of ONFH (P = 0.003, OR = 0.605 95% CI: 0.430 \~ 0.852), whereas the haplotype C-G (P = 0.002, OR = 2.223; 95% CI: 1.144 \~ 3.361) was significantly associated with an increased risk of ONFH. No significant association was observed between the haplotype T-G and C-C and ONFH.Table 3**Distribution of haplotypesHaplotypeONFHControl*P*OR (95% CI)**T-C0.1090.2470.0030.605 \[0.430 \~ 0.852\]T-G0.2130.1950.1991.455 \[0.796 \~ 4.905\]C-C0.1430.1520.1170.936 \[0.811 \~ 1.982\]C-G0.1220.0600.0022.223 \[1.144 \~ 3.361\]

ApoA5 genetic polymorphisms and lipids levels {#Sec12}
---------------------------------------------

In addition, age and sex adjusted intergenotypic variations in lipid levels with respect to *apoA5* polymorphisms have been summarized in Table [4](#Tab4){ref-type="table"}. Rare C allele of rs662799 and G allele of rs3135506 carriers were associated with higher levels of TG in ONFH patients (both *P* \< 0.05).Table 4**Comparison of lipids levels between each genotypers662799rs3135506ParametersGroupsTTTC/CCCCCG/GGP\*P\*\***TC (mg/dl)Case5.0 ± 2.7 (n = 146)5.2 ± 2.5 (n = 77)5.2 ± 2.6 (n = 159)5.0 ± 2.2 (n = 65)0.1250.442Control4.4 ± 2.1 (n = 192)4.9 ± 2.4 (n = 9)4.6 ± 2.3 (n = 176)4.8 ± 2.1 (n = 25)0.1120.314LDL-C (mg/dl)Case2.6 ± 1.22.9 ± 1.32.7 ± 1.12.6 ± 1.30.1090.197Control2.3 ± 1.32.5 ± 1.22.4 ± 1.12.5 ± 1.30.2210.453HDL-C (mg/dl)Case1.8 ± 0.91.6 ± 0.71.6 ± 0.81.7 ± 0.80.1980.3381Control1.7 ± 1.01.6 ± 0.81.6 ± 1.01.4 ± 0.80.3320.143TG (mg/dl)Case2.1 ± 1.42.7 ± 0.82.0 ± 1.02.8 ± 0.90.0130.024Control1.7 ± 0.81.6 ± 1.11.8 ± 0.91.5 ± 1.10.4350.174Note: TC = Total cholesterol; LDL-C = Low-density lipoprotein-cholesterol; LDL-C = High-density lipoprotein-cholesterol; TG = Triglycerides; \*P value for rs662799; \*\*P value for rs3135506.

Discussion {#Sec13}
==========

In the present study, we found that in patients with ONFH, C allele of rs662799 and G allele of rs3135506 in apoA5 gene were significantly higher than that in the control group, the T-C haplotype frequency was significantly lower than that in the control group (*P* \<0.0001) and C-G haplotype was common in the control group. This is the first study to clarify the relation between *ApoA5* polymorphism and ONFH.

The abnormal lipid metabolism and intravascular coagulation composed the main pathogenesis of osteonecrosis \[[@CR3]\]. Hyperlipidemia affected the microcirculation of the femoral head resulting in femoral necrosis from multiple links, such as affecting blood coagulation solvent systems, influencing bone fat embolism, and affecting the formation of bone micro-thrombosis \[[@CR21],[@CR22]\]. Many evidences showed that *ApoA5* gene is associated with serum lipid levels \[[@CR10]\]. Recent findings indicate that *ApoA5* could also influence cholesterol homeostasis and probably could play a role in hypertriglyceridemia \[[@CR11]\]. In our study, we found polymorphisms of *ApoA5* gene are associated with TG levels. The carriers with mutant alleles have higher levels of TG in the ONFH patients. Therefore, we consider the mechanism of the association of *ApoA5* polymorphisms with ONFH may resulting from lipids level changes caused by *ApoA5* genetic polymorphism.

Although we found a positive association between *ApoA5* polymorphisms and ONFH, the present study was limited by the relatively small sample size. This may have led to weak statistical significance and wide CIs when estimating odds ratios. In addition, we did not perform functional study of these two SNPs, which may be another limitation of our study.

Conclusion {#Sec14}
==========

In conclusion, this study showed that *ApoA5* polymorphism may be associated with ONFH in Han Chinese population.
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